

Suppl. Table 1: Patients characteristics

Patient ID	Cancer type	Histopathology	Stage	Material	Treatment prior to surgery	Gender	Age (y)	CD3+ (%)	CD8+ (% of CD3+)	CD4+ (% of CD3+)
BS-199	NSCLC	Adenocarcinoma	IV	pleural effusion	no	male	68	4.53	6.57	61.4
BS-213	EOC	Adenocarcinoma (endometrioid)	II	solid tumor	no	female	90	2.53	34.9	56.3
BS-256	EOC	serous Adenocarcinoma	IIIB	solid tumor	no	female	60	26.7	21.7	57.4
BS-285	EOC	Mucinous Adenocarcinoma/Borderline	IA	solid tumor	no	female	78	1.45	6.21	40.7
BS-390-2	NSCLC	Squamous	IIIA	solid tumor	no	female	62	22.30	34.10	54.30
BS-428	EOC	serous Adenocarcinoma	IIIA	solid tumor		female	48	19.60	54.90	32.10
BS-504	NSCLC	Adeno	IB	solid tumor	no	female	78	31.70	33.10	57.30
BS-505	NSCLC	Squamous	IA	solid tumor	no	male	72	39.60	36.20	48.10
BS-508	NSCLC	Adeno	IIIA	solid tumor	no	male	68	29.00	33.70	53.40
BS-515T	NSCLC	Squamous	IIIB	solid tumor	no	male	67	71.10	37.90	49.30
BS-524	NSCLC	Large Cell	IV (CNS)	solid tumor	no	male	54	59.70	72.90	6.82
BS-534	EOC	serous Adenocarcinoma	IIIC	solid tumor	no	female	67	11.30	45.10	31.20
BS-537	NSCLC	Squamous	IA	solid tumor	no	male	76	13.10	58.80	19.30
BS-538	NSCLC	Adeno	IIIA	solid tumor	chemotherapy	male	62	10.70	53.50	22.00
BS-540	NSCLC	Squamous	IIA	solid tumor	no	male	80	28.70	22.40	67.20
BS-542	NSCLC	Squamous	IA	solid tumor	no	male	76	59.60	55.20	37.00
BS-564	NSCLC	Squamous (also mesothelioma detected)	IA	solid tumor	no	male	73	78.50	52.10	42.80
BS-597	EOC	serous Adenocarcinoma	IVB	solid tumor	no	female	53	82.20	52.10	40.70